Advanced Imaging Modalities for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer’s Disease: A Collaborative Prospective Study
Poster: 95167 | Jude-Patrick Nnamdi Okafor, MD, et al. Learn More
Portable, Low-field MRI for Alzheimer’s Disease
Poster: 35305 | W. Taylor Kimberly, MD, PhD, et al. Learn More
The Swoop portable ultra‑low‑field MR brain imaging system is a groundbreaking technology that expands access to care.
Plug and scan. Simply plug the system into a standard electrical outlet, and within two minutes, you can begin scanning using the intuitive tablet interface—no need for an MRI tech in most states.*
Patient friendly. Compared to conventional MRI, the system offers a quieter experience, allows care partners to stay bedside, and provides the convenience of imaging and clinical visit at a single location.
Safe for standalone use. The ultra-low field strength (0.064T) is safe to operate in a medical office without burdensome shielding requirements.
Affordable. The system costs significantly less to acquire and maintain than conventional MRI machines.
The Swoop system is FDA-cleared with established reimbursement and is currently being used in fifteen countries around the world.
*Requirements vary by state and institution.
You can now bring MR brain imaging to any professional healthcare setting.
By incorporating the Swoop system into your office or infusion center, you can ensure safe and timely ARIA-E monitoring for your patients who are undergoing amyloid-targeting therapies.
The Swoop system can be used in:
Physician offices
Dementia clinics
Infusion centers
Hospitals
CARE PMR: ARIA research using the Swoop system.
Capturing ARIA Risk Equitably with Portable MR
Prospective multi-site observational study designed to assess the clinical utility and workflow benefits of using portable Swoop system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy.
Investigators:
Dr. Tammie Benzinger (Principal Investigator), Washington University School of Medicine
Dr. Teresa Gomez-Isla, Massachusetts General Hospital
Dr. W. Taylor Kimberly, Massachusetts General Hospital
Enrollment target:
50 confirmed ARIA cases
This observational study aims to assess Swoop system images and determine:
The reliability to detect the presence of clinical actionable ARIA-E compared to the standard of care
The absence of ARIA-E in asymptomatic patients as sufficient condition for continuing with therapy
The feasibility of deploying the Swoop system at infusion centers or clinics for ARIA monitoring
The Swoop® system brings MR brain imaging within reach.
The Swoop system brings brain imaging within reach for clinicians to help them make clinical decisions in a variety of healthcare settings across a range of conditions. The first FDA-cleared portable MR brain imaging system that combines safe, ultra-low-field magnetic resonance with proprietary artificial intelligence, the Swoop system potentially enables timelier treatment decisions, quicker discharges, and more efficient use of staff and hospital resources.
